Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2001;32:1385-1393

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quilliam, B. J.
Right arrow Articles by Leibson, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quilliam, B. J.
Right arrow Articles by Leibson, C.
Related Collections
Right arrow Secondary prevention
Right arrow Anticoagulants
Right arrow Antiplatelets
Right arrow Epidemiology

(Stroke. 2001;32:1385.)
© 2001 American Heart Association, Inc.


Original Contributions

Clinical Correlates and Drug Treatment of Residents With Stroke in Long-Term Care

Brian J. Quilliam, PhD Kate L. Lapane, PhD

From Brown University Department of Community Health (B.J.Q., K.L.L.) and Brown University Center for Gerontology and Health Care Research (K.L.L.), Providence, RI.

Correspondence to Kate L. Lapane, PhD, Brown University, Box G-B222, Providence, RI 02912. E-mail Kate_Lapane{at}brown.edu

Background and Purpose—Stroke incidence increases with age, and stroke survivors often require nursing home placement. Characteristics of these residents and factors associated with the secondary drug prevention of stroke in nursing homes have yet to be explored.

Methods—We used a population-based data set of all nursing home residents in 5 states (1992 to 1995). We identified 53 829 (20.4%) with a diagnosis of stroke on the Minimum Data Set assessment. We considered aspirin, dipyridamole, ticlopidine, or warfarin alone or in combination as secondary drug prevention. We used logistic regression modeling to identify independent predictors of drug treatment.

Results—Sixty-seven percent of stroke survivors were not receiving drug therapy for stroke prevention. Among those treated, most received aspirin alone (16%) or warfarin alone (10%). Independent predictors of drug treatment included comorbid conditions (eg, hypertension, atrial fibrillation, depression, Alzheimer’s disease, dementia, gastrointestinal bleeding, and peptic ulcer disease). Those over the age of 85 years were less likely to be treated than those 65 to 74 years of age (odds ratio [OR], 0.86; 95% confidence interval [CI], 0.82 to 0.91); black residents were less likely to be treated than whites (OR, 0.80; 95% CI, 0.75 to 0.85); and those with severe cognitive (OR, 0.63; 95% CI, 0.60 to 0.67) or physical impairment (OR, 0.69; 95% CI, 0.64 to 0.75) were also less likely to receive drug treatment.

Conclusions—Stroke is highly prevalent in long-term care. Despite the increased risk of subsequent stroke in the elderly, many are not being treated. The choice to treat or not to treat may be influenced by age, comorbidity, race/ethnicity, and cognitive or physical functioning.

Editorial Comment

Cynthia Leibson, PhD, Guest Editor

Department of Health Sciences Research, Mayo Clinic Foundation, Rochester, Minnesota




This article has been cited by other articles:


Home page
StrokeHome page
B. Ovbiagele, O. Drogan, W. J. Koroshetz, P. Fayad, and J. L. Saver
Outpatient Practice Patterns After Stroke Hospitalization Among Neurologists
Stroke, June 1, 2008; 39(6): 1850 - 1854.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
N. A. Nickman, J. Biskupiak, F. Creekmore, H. Shah, and D. I . Brixner
Antiplatelet medication management in patients hospitalized with ischemic stroke
Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2250 - 2256.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
B. Ovbiagele, N. K. Hills, J. L. Saver, S. C. Johnston, and for the CASPR Investigators
Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA
Neurology, February 14, 2006; 66(3): 313 - 318.
[Abstract] [Full Text] [PDF]


Home page
Clin RehabilHome page
L. Leeds, J. Meara, and P. Hobson
The impact of discharge to a care home on longer term stroke outcomes
Clinical Rehabilitation, August 1, 2004; 18(8): 924 - 928.
[Abstract] [PDF]


Home page
StrokeHome page
J. B. Christian, K. L. Lapane, and R. S. Toppa
Racial Disparities in Receipt of Secondary Stroke Prevention Agents Among US Nursing Home Residents
Stroke, November 1, 2003; 34(11): 2693 - 2697.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
F Landi, M Cesari, G Onder, V Zamboni, F Lattanzio, A Russo, C Barillaro, and R Bernabei
Antithrombotic drugs in secondary stroke prevention among a community dwelling older population
J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1100 - 1104.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
B. J. Quilliam, K. L. Lapane, C. B. Eaton, and V. Mor
Effect of Antiplatelet and Anticoagulant Agents on Risk of Hospitalization for Bleeding Among a Population of Elderly Nursing Home Stroke Survivors
Stroke, October 1, 2001; 32(10): 2299 - 2304.
[Abstract] [Full Text] [PDF]